Roche scores double cancer approval for new Bayer rival Rozlytrek

Roche’s targeted cancer drug Rozlytrek officially has its U.S. green light—and in not just one, but two cancer types. Thursday, the FDA cleared the med to treat ROS1-positive non-small cell lung cancer and tough-to-treat NTRK fusion-positive tumors.